Immunovant stopped development of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus after failing to meet a midphase endpoint in the program. The decision closes one potential path to market for the anti-FcRn approach. The termination highlights the steep attrition rates in autoimmune drug development, where even biologically grounded targets face mixed translation from proof-of-mechanism into robust clinical effects across endpoints. From a competitive standpoint, the retreat may redirect resources toward other FcRn assets or alternative autoimmune targets. It also leaves room for other companies pursuing FcRn or adjacent immunomodulation strategies in lupus. For the broader biotech audience, the readout is another reminder that CGT’s durability race and oncology’s biomarker arms race are not the only areas of high-stakes attrition; autoimmune pipeline bets continue to face tight clinical bars.